Pure antiestrogen-induced G1-arrest in myeloma cells results from the reduced kinase activity of cyclin D3/CDK6 complexes whereas apoptosis is mediated by endoplasmic reticulum-dependent caspases

International Journal of Cancer

Volumn 122, Issue 9, 2008, Pages 2130-2141

  Gauduchon, Juliette ^a   Seguin, Amélie ^a   Marsaud, Véronique ^b,c   Clay, Denis ^c,d   Renoir, Jack Michel ^b,c   Sola, Brigitte ^a,e  

^a UNIVERSITÉ DE CAEN   (France)

^b UNIV PARIS SUD   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e CHU CÔTE DE NACRE   (France)

Author keywords

Antiestrogenic therapy; Apoptosis; Multiple myeloma; Pure antiestrogen; Survival pathway

Indexed keywords

11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 4 HYDROXYTAMOXIFEN; ANTIESTROGEN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CASPASE; CD19 ANTIGEN; CYCLIN D3; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DEXAMETHASONE; FULVESTRANT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOCHONDRIAL ENZYME; MYC PROTEIN; PHOSPHOTRANSFERASE; RETINOBLASTOMA PROTEIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SYNDECAN 1; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BORONIC ACID DERIVATIVE; CDK6 PROTEIN, HUMAN; CYCLINE; DRUG DERIVATIVE; ESTRADIOL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PYRAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MYELOMA CELL; PRIORITY JOURNAL; SURVIVAL; UPREGULATION; CELL CULTURE; CELL PROLIFERATION; COLORIMETRY; DRUG RESISTANCE; FLOW CYTOMETRY; IMMUNOPRECIPITATION; METABOLISM; MITOCHONDRION; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; CASPASES; CELL PROLIFERATION; COLORIMETRY; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENDOPLASMIC RETICULUM; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FLOW CYTOMETRY; G1 PHASE; HUMANS; IMMUNOPRECIPITATION; MITOCHONDRIA; MULTIPLE MYELOMA; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZINES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 40749119799     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23310     Document Type: Article

References (59)

1. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998;91:3-21.
2. Kuehl W, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002;2:175-87.
3. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104:607-18.
4. Danel L, Menouni M, Cohen JH, Magaud JP, Lenoir G, Revillard JP, Saez S. Distribution of androgen and estrogen receptors among lymphoid and haemopoietic cell lines. Leuk Res 1985;9:1373-8.
5. Danel L, Vincent C, Rousset F, Klein B, Bataille R, Flacher M, Durie BG, Revillard JP. Estrogen and progesterone receptors in some human myeloma cell lines and murine hybridomas. J Steroid Biochem 1988;30:363-7.
6. Treon SP, Teoh G, Urashima M, Ogata A, Chauhan D, Webb IJ, Anderson KC. Anti-estrogens induce apoptosis of multiple myeloma cells. Blood 1998;92:1749-57.
7. Otsuki T, Yamada O, Kurebayashi J, Moriya T, Sakaguchi H, Kunisue H, Yata K, Uno M, Yawata Y, Ueki A. Estrogen receptors in human myeloma cells. Cancer Res 2000;60:1434-41.
8. Kip1 and modulation of Bcl-2 family members. Clin Cancer Res 2005;11:2345-54.
9. Olivier S, Close P, Castermans E, de Leval L, Tabruyn S, Chariot A, Malaise M, Merville MP, Bours V, Franchimont N. Raloxifene-induced myeloma cell apoptosis: a study of NF-κB inhibition and gene expression signature. Mol Pharmacol 2006;69:1615-23.
10. Maillard S, Gauduchon J, Marsaud V, Gouilleux F, Connault E, Opolon P, Fattal E, Sola B, Renoir J-M. Improved antitumoral properties of pure antiestrogen RU 58668-Ioaded liposomes in multiple myeloma. J Steroid Biochem Mol Biol 2006;100:67-78.
11. Carroll JS, Lynch DK, Swarbrick A, Renoir JM, Sarcevic B, Daly RJ, Musgrove EA, Sutherland RL. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells. Cancer Res 2003;63:4322-6.
12. Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattachary N, Slingerland JM. Downregulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci USA 2000;97:9042-6.
13. Carroll JS, Prall OW, Musgrove EA, Sutherland RL. A pure estrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130/E2F4 complexes characteristic of quiescence. J Biol Chem 2000;275:38221-9.
14. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-5.
15. Kip1 by two mechanisms, ubiquitin-mediated degradation and proteolyitic processing. J Biol Chem 1999;274:13886-93.
16. Sanhes L, Tang R, Delmer A, DeCaprio JA, Ajchenbaum-Cymbalista F. Fludarabine-induced apoptosis of B chronic lymphocytic leukemia cells includes early cleavage of p27kip1 by caspases. Leukemia 2003;17:1104-11.
17. Carroll JS, Swarbrick A, Musgrove EA, Sutherland RL. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Cancer Res 2002;62:3126-33.
18. Thiantanawat A, Long BJ, Brodie AM. Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res 2003;63:8037-50.
19. Varshochi R, Halim F, Sunters A, Alao JP, Madureira PA, Hart SM, Ali S, Vigushin DM, Coombes RC, Lam EW. ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor α from SP1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line. J Biol Chem 2005;280:3185-96.
20. Lesage D, Troussard X, Sola B. The enigmatic role of cyclin D1 in multiple myeloma. Im J Cancer 2005;115:171-6.
21. Gu Y, Rosenblatt J, Morgan DO. Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J 1992;11:3995-4005.
22. Sherr C, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004;18:2699-711.
23. Ely S, Di Liberto M, Niesvizky R, Baughn LB, Cho HJ, Hatada EN, Knowles DM, Lank J, Chen-Kiang S. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res 2005;65:11345-53.
24. Zarkowska T, Mittnacht S. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem 1997;272:12738-46.
25. Chauhan D, Hideshima T, Rosen S, Reed JC, Kharbanda S, Anderson KC. Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J Biol Chem 2001;276:24453-6.
26. Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, Munshi N, Kharbanda S, Anderson KC. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem 2003;78:17593-6.
27. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2000;99:1885-93.
28. Obeng EA, Boise LH. Caspase-12 and caspase-4 are not required for caspase-dependent endoplasmice reticulum stress-induced apoptosis. J Biol Chem 2005;280:29578-87.
29. Pelletier N, Casamayor-Pallejà M, De Luca K, Mondière P, Saltel F, Jurdic P, Bella C, Genestier L, Defrance T. The endoplasmic reticulum is a key component of the plasma cell death pathway. J Immunol 2006;176:1340-7.
30. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001;98:795-804.
31. Scheidereit C. IκB kinase complexes: gateways to NF-κB activation and transcription. Oncogene 2006;25:6685-705.
32. van de Donk NWCJ, Lokhorst HM, Bloem AC. Growth factors and antiapoptotic signaling pathways in multiple myeloma. Leukemia 2005;19:2177-85.
33. Hayun M, Naor Y, Weil M, Albeck M, Peled A, Don J, Haran-Ghera N, Sredni B. The immunomodulator AS101 induces growth arrest and apoptosis in multiple myeloma: association with the Akt/survivin pathway. Biochem Pharmacol 2006;72:1423-31.
34. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG, Anderson KC. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma. Blood 2006;15:4053-62.
35. Rizvi MA, Ghias K, Davies KM, Ma C, Weinberg F, Munshi HG, Krett NL, Rosen ST. Enzastaurin (LY317615), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma. Mol Cancer Ther 2006;5:1783-9.
36. Hideshima T, Chauhan D, Richardson P, Anderson KC. Identification of novel therapeutic targets for multiple myeloma. J Clin Oncol 2005;23:6345-50.
37. Cavo M. Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 2006;20:1341-52.
38. Crawford LJA, Walker B, Ovaa H, Chauhan D, Anderson KC, Morris TCM, Irvine AE. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res 2006;66:6379-86.
39. Ponzielli R, Katz S, Barsyte-Lovejoy D, Penn LZ. Cancer therapeutics: targeting the dark site of Myc. Eur J Cancer 2005;41: 2485-501.
40. Mukherjee S, Conrad SE. c-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells. J Biol Chem 2005;280:17617-25.
41. Venditti M, Iwasiow B, Orr FW, Shiu RP. c-Myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells. Int J Cancer 2002;99:39-42.
42. Fink JR, LeBien TW. Novel expression of cyclin-dependent kinase inhibitors in human B-cell precursors. Exp Hematol 2001;29:490-8.
43. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J, Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005;106:296-303.
44. Taniguchi T, Endo H, Chikatsu N, Uchimaru K, Asano S, Fujita T, Takahata T, Motokura T. Expression of p21Cip1/Waf1/Sdi1 and p27Kip1 cyclin-dependent kinase inhibitors during human hematopoiesis. Blood 1999;93:4167-78.
45. Park WH, Seol JG, Kim ES, Jung CW, Lee CC, Binderup L, Koeffler HP, Kim BK, Lee YY. Cell cycle arrest induced by the vitamin D3 analog EB1089 in NCI-H929 myeloma cells is associated with induction of the cyclin-dependent kinase inhibitor p27. Exp Cell Res 2000;254:279-86.
46. Strömberg T, Dimberg A, Hammarberg A, Carlson K, Osterborg A, Nilsson K, Jemberg-Wiklund H. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 2004;103:3138-47.
47. Philipp A, Schneider A, Vasrik I, Finke K, Xiong Y, Beach D, Alitalo K, Eilers M. Repression of cyclin D1: a novel function of MYC. Mol Cell Biol 1994;14:4032-43.
48. Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorge W, Reed S, Sicinski P, Bartek J, Eilers M. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J 1999;18:5321-33.
49. Perez-Roger I, Kim SH, Griffiths B, Sewing A, Land H. Cyclins D1 and D2 mediate myc-induced cell proliferation via sequestration of p27(Kip1) and p21(Cip1). EMBO J 1999;18:5310-20.
50. O'Hagan RC, Ohh M, David G, de Alboran IM, Alt FW, Kallin WG Jr, DePinho RA. Myc-enhanced expression of Cull promotes ubiquitin-dependent proteolysis and cell cycle progression. Genes Dev 2000;14:2185-91.
51. Ausserlechner MJ, Obexer P, Böck G, Geley S, Kofler R. Cyclin D3 and c-MYC control glucocorticoid-induced cell cycle arrest but not apoptosis in lymphoblastic leukemia cells. Cell Death Differ 2004;11:165-74.
52. Chandramohan V, Jeay S, Pianetti S, Sonenshein GE. Reciprocal control of Forkhead box O3a and c-Myc via the phosphatidylinositol 3-kinase pathway co-ordinately regulates p27Kip1 levels. J Immunol 2004;172:5522-7.
53. Pei X-H, Xiong Y. Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues. Oncogene 2005;24:2787-95.
54. Mateyak MK, Obaya AJ, Sedivy JM. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol 1999;19:4672-83.
55. de Alboran IM, O'Hagan R, Gärtner F, Malynn B, Davidson L, Rickert R, Rajewsky K, DePinho RA, Alt FW. Analysis of c-MYC function in normal cells via conditional gene-targeted mutation. Immunity 2001;14:45-55.
56. Shammas MA, Neri P, Koley H, Batchu RB, Bertheau RC, Munshi V, Prabhala R, Fulciniti M, Tai YT, Treon SP, Goyal RK, Anderson KC, et al. Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood 2006;108:2804-10.
57. Fribley A, Wang CY. Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress. Cancer Biol Ther 2006;5:745-8.
58. Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907-16.
59. Burger R, Guenther A, Bakker F, Schmalzing M, Bernand S, Baum W, Duerr B, Hocke GM, Steininger H, Gebhart E, Gramatzki M. Gp130 and ras mediated signalling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. Hematol J 2001;2:42-53.